Sichuan Goldstone Asia Pharmaceutical, Inc. (300434.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

16.3x

Market Cap

CNY 4.53B

MomentumView details →

1D Return

−4.81%

YTD Return

+6.91%

RSI (14)

44.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

16.3x

Market Cap

CNY 4.53B

RSI (14)

44.8

MomentumView details →

1D Return

−4.81%

YTD Return

+6.91%

ProfitabilityView details →

Gross Margin

59.72%

Net Margin

17.14%

EBITDA Margin

23.85%

ROE (TTM)

6.93%

ROA (TTM)

5.82%

Asset Turnover

0.34x

GrowthView details →

Revenue YoY

+4.59%

EPS YoY

+187.22%

FCF YoY

−24.20%

Revenue CAGR 3Y

−5.81%

EPS CAGR 3Y

−15.14%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

2.90x

Quick Ratio

2.44x

Div Yield

0.75%

Div Rate

CNY 0.08

Div Growth 1Y

+18.84%

Financials snapshotView financials →

Revenue (TTM)

1.08B

Net Income (TTM)

184.79M

Op. CF (TTM)

193.34M

Latest newsMore news →

Zhejiang Di'er Pharmaceutical Co., Ltd.'s diclofenac sodium sustained-release tablets are provisionally selected in the 12th national centralized drug procurement; the product's 2025 sales revenue was 6.2231 million yuan, accounting for 0.60% of the company's 2025 operating revenue.34d ago

Similar companies

新瀚新材301076.SZ 尤夫股份002427.SZ 七彩化学300758.SZ 善水科技301190.SZ 华纬科技001380.SZ 民生健康301507.SZ Find similar companies →

Latest newsMore news →

Zhejiang Di'er Pharmaceutical Co., Ltd.'s diclofenac sodium sustained-release tablets are provisionally selected in the 12th national centralized drug procurement; the product's 2025 sales revenue was 6.2231 million yuan, accounting for 0.60% of the company's 2025 operating revenue.34d ago